Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.

Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. Abstract Text:

Robin DiFrancesco,Margaret A Fischl,Julie Donnelly,Barry S Zingman,Elinore F McCance-Katz,David E Moody,Richard C Reichman,Barbara Gripshover,Gene D Morse,

The availability of buprenorphine (BUP) provides an alternative approach to the treatment of opioid addiction with methadone, an agent that has many drug-drug interactions when combined with antiretroviral therapy (ART). However, due to limited long-term pharmacokinetic studies in HIV-infected patients, the clinical use of BUP, a CYP450-3A4 substrate, will require that studies be conducted to examine safety, tolerability and pharmacokinetics when these drugs are taken for chronic treatment. One clinical approach could include plasma concentration monitoring to avoid under- or overdosing BUP secondary to drug interactions with ART. The measurement of BUP and its active metabolite, norbuprenorphine (NBUP) facilitates the addition of BUP to ART in an attempt to avoid drug toxicity as described in a recent report by Bruce et al. Therefore, our objective was to validate a BUP assay and integrate its application into an ongoing antiretroviral (ARV) plasma concentration monitoring program. A chromatographic method for monitoring BUP and its active metabolite, NBUP was investigated. An assay was developed that would facilitate BUP and ARV measurement from a single 3 mL blood sample (0.75 mL plasma required) in conjunction with a previously validated multiple ARV HPLC method. The method measures BUP and NBUP over the range from 0.25 to 50 ng/mL with mass spectrometry detection. Inter- and intra-assay variation was

Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. Publishing Authors By Initials

R DiFrancesco,MA Fischl,J Donnelly,BS Zingman,EF McCance-Katz,DE Moody,RC Reichman,B Gripshover,GD Morse,

For similar investigative techniques: chemistry, analytical: mass spectrometry: tandem mass spectrometry research abstracts see: investigative techniques: chemistry, analytical: mass spectrometry: tandem mass spectrometry research

PUBMED ID PMID:

MEDLINE DATE:

Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of pharmaceutical and biomedical analysis

VOLUME: 44

Page Numbers: 188-95

Journal Abbreviation:

ISSN: 0731-7085

DAY: 16

MONTH: 02

YEAR: 2007

Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309336

Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. Keywords Mesh Terms:

KEYWORDS: Tandem Mass Spectrometry

MESH TERMS: methods

Chemical & Substance for Abstract: Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. Information

Substance Name: Buprenorphine

Registry Number: 52485-79-7

Grant and Affiliation Information for Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.

AFFILIATION: Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.

Country: England

AGENCY: United States PHS

GRANT: SIORRR14572

ACRONYM: DA

MEDLINETA: J Pharm Biomed Anal

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users Related Publications

• A dinoflagellate AAA family member rescues a conditional yeast G1/S phase cyclin mutant through increased CLB5 accumulation.
• Advances in pharmacogenomics of antiretrovirals: an update.
• Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells.
• Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
• Bone morphogenetic protein receptor 2 mutations in pulmonary hypertension.
• Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.
• Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks.
• Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry.
• Direct selection of RNA beacon aptamers.
• Drug interactions between proton pump inhibitors and antiretroviral drugs.
• Duplicate publication.
• Effects of pyriproxyfen on California red scale (Hemiptera: Diaspididae) development and reproduction.
• Functional deficiency in IL-7 caused by an N-ethyl-N-nitrosourea-induced point mutation.
• Genome-wide analysis of transcriptional dependence and probable target sites for Abf1 and Rap1 in Saccharomyces cerevisiae.
• Global infectious disease surveillance and health intelligence.
• Global preparedness for public health emergencies.
• HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries.
• Hierarchical assembly of the siliceous skeletal lattice of the hexactinellid sponge Euplectella aspergillum.
• High resolution Fourier-domain optical coherence tomography of retinal angiomatous proliferation.
• Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.
• Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.
• Pandemic influenza: studying the lessons of history.
• Rotationally resolved spectroscopy of jet-cooled NbMo.
• Simulations of dynamics and viscoelasticity in highly entangled solutions of semiflexible rods.
• Technology evaluation: BLP-25, Biomira Inc.
• The US pandemic influenza implementation plan at six months.
• Toxicity of systemic neonicotinoid insecticides to avocado thrips in nursery avocado trees.
• Transcription factor access to promoter elements.
• Use of the finite element method to assess impact of current on forearm and wrist during an electrical accident.
• Wide dynamic range germanium detector for perturbation crystallography.